美国18-64岁糖尿病患者自付费用的全国趋势:2001-2017
该研究利用2001-2017年医疗支出面板调查数据,评估美国18-64岁糖尿病成人自付费用趋势。结果显示自付费用从4328美元降至4139美元(下降4.3%),高自付费用率从28%降至19%(P<0.001)。公共保险或无保险及低收入人群高自付费用率下降,而私人保险和高收入人群保持稳定。
要点
- 2001-2017年美国非老年糖尿病患者自付费用下降4.3%,高自付费用率从28%降至19%。
- 公共保险或无保险及收入低于联邦贫困线200%的人群高自付费用率下降明显。
- 胰岛素使用者总自付费用和处方药自付费用下降幅度大于非胰岛素使用者。
核心结论
- 美国18-64岁糖尿病成人自付费用下降,尤其在经济负担能力最差的人群中。
研究设计与样本
- 基于2001-2017年医疗支出面板调查数据的回顾性趋势分析,估算人均年自付费用和高自付费用率(自付支出>家庭税前收入10%)。
主要发现
- 自付费用从4328美元降至4139美元,下降4.3%。
- 高自付费用率从28%降至19%(P<0.001)。
- 公共保险或无保险及收入低于联邦贫困线200%的人群高自付费用率下降(P<0.001),私人保险和高收入人群保持稳定。
- 所有亚组处方药自付费用均下降(P<0.001)。
- 胰岛素使用者总自付费用下降58美元 vs 非使用者37美元(P<0.001),处方药自付费用下降79美元 vs 68美元(P<0.001)。
临床怎么用
- 关注糖尿病患者的自付费用负担,尤其私人保险和高收入人群的高自付费用率未下降。
局限性
- 未来研究可探讨自付费用下降的影响因素及其对糖尿病护理质量和并发症率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess national trends in out-of-pocket (OOP) costs among adults aged 18-64 years with diabetes in the U.S. RESEARCH DESIGN AND METHODS: Using data from the 2001-2017 Medical Expenditure Panel Survey, we estimated total per person annual OOP costs (insurance premiums, prescription drug costs, inpatient and outpatient deductibles, copays, and other payments not covered by insurance) and high OOP cost rate, defined as the percentage of people with OOP spending >10% of their family's pretax income. We examined trends overall, by subgroup (insurance type, income level, insulin use, size of patient's employer, and whether the patient was enrolled in a high deductible health plan), and by type of service. Changes in trends were identified using joinpoint analysis; costs were adjusted to 2017 U.S. dollars. RESULTS: From 2001 to 2017, OOP costs decreased 4.3%, from $4,328 to $4,139, and the high OOP cost rate fell 32%, from 28 to 19% (P < 0.001). Changes in the high OOP cost rate varied by subgroup, declining among those with public or no insurance and those with an income <200% of the federal poverty level (P < 0.001) but remaining stable among those with private insurance and higher income. Drug prescription OOP costs decreased among all subgroups (P < 0.001). Decreases in total (-$58 vs. -$37, P < 0.001) and prescription (-$79 vs. -$68, P < 0.001) OOP costs were higher among insulin users than noninsulin users. CONCLUSIONS: OOP costs among U.S. nonelderly adults with diabetes declined, especially among those least able to afford them. Future studies may explore factors contributing to the decline in OOP costs and the impact on the quality of diabetes care and complication rates.
引用
- Wang Y, Park J, Li R, et al. National Trends in Out-of-Pocket Costs Among U.S. Adults With Diabetes Aged 18-64 Years: 2001-2017. Diabetes Care. 2021. PMID: 34429323. doi:10.2337/dc20-2833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。